| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 91 | 2025 | 103 | 19.440 |
Why?
|
| Glaucoma, Open-Angle | 73 | 2025 | 76 | 16.050 |
Why?
|
| Intraocular Pressure | 111 | 2025 | 127 | 10.060 |
Why?
|
| Visual Fields | 57 | 2025 | 70 | 7.870 |
Why?
|
| Humans | 282 | 2026 | 6794 | 7.740 |
Why?
|
| Aged | 156 | 2026 | 1539 | 7.210 |
Why?
|
| Female | 201 | 2026 | 4060 | 6.920 |
Why?
|
| Vision Disorders | 33 | 2023 | 52 | 6.910 |
Why?
|
| Medicare | 19 | 2026 | 57 | 6.800 |
Why?
|
| Male | 175 | 2026 | 3671 | 6.410 |
Why?
|
| Trabeculectomy | 36 | 2025 | 40 | 6.220 |
Why?
|
| Visual Acuity | 49 | 2022 | 123 | 5.960 |
Why?
|
| Ophthalmology | 20 | 2024 | 39 | 5.950 |
Why?
|
| Aged, 80 and over | 90 | 2026 | 497 | 5.140 |
Why?
|
| United States | 64 | 2026 | 1019 | 5.010 |
Why?
|
| Retrospective Studies | 74 | 2025 | 681 | 4.940 |
Why?
|
| Cataract Extraction | 11 | 2026 | 16 | 4.620 |
Why?
|
| Medicare Part B | 15 | 2025 | 15 | 4.310 |
Why?
|
| Vision Screening | 10 | 2022 | 10 | 4.160 |
Why?
|
| Cross-Sectional Studies | 59 | 2026 | 506 | 4.110 |
Why?
|
| Eye Diseases | 11 | 2025 | 34 | 4.050 |
Why?
|
| Glaucoma Drainage Implants | 24 | 2025 | 27 | 3.980 |
Why?
|
| Middle Aged | 108 | 2025 | 2108 | 3.820 |
Why?
|
| Macular Degeneration | 18 | 2025 | 20 | 3.650 |
Why?
|
| Refractive Errors | 10 | 2020 | 10 | 3.390 |
Why?
|
| Optic Nerve Diseases | 28 | 2025 | 31 | 3.330 |
Why?
|
| Prevalence | 36 | 2025 | 259 | 3.160 |
Why?
|
| Cataract | 13 | 2026 | 20 | 3.160 |
Why?
|
| Risk Factors | 57 | 2025 | 767 | 3.140 |
Why?
|
| Optic Disk | 28 | 2025 | 29 | 3.000 |
Why?
|
| Visual Field Tests | 24 | 2025 | 32 | 2.840 |
Why?
|
| Strabismus | 9 | 2025 | 9 | 2.840 |
Why?
|
| Follow-Up Studies | 45 | 2025 | 268 | 2.470 |
Why?
|
| Vision, Low | 8 | 2023 | 10 | 2.440 |
Why?
|
| Adult | 66 | 2025 | 2113 | 2.250 |
Why?
|
| Exfoliation Syndrome | 11 | 2021 | 12 | 2.220 |
Why?
|
| Amblyopia | 6 | 2021 | 6 | 2.180 |
Why?
|
| Prospective Studies | 44 | 2025 | 331 | 2.140 |
Why?
|
| Tomography, Optical Coherence | 23 | 2025 | 48 | 2.090 |
Why?
|
| Quality of Life | 11 | 2023 | 184 | 1.990 |
Why?
|
| Diabetic Retinopathy | 8 | 2025 | 52 | 1.990 |
Why?
|
| Retinal Ganglion Cells | 18 | 2025 | 20 | 1.980 |
Why?
|
| California | 11 | 2026 | 230 | 1.940 |
Why?
|
| Delivery of Health Care | 6 | 2020 | 71 | 1.900 |
Why?
|
| Mass Screening | 4 | 2024 | 116 | 1.880 |
Why?
|
| Postoperative Complications | 19 | 2020 | 109 | 1.860 |
Why?
|
| Endophthalmitis | 4 | 2022 | 10 | 1.840 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 172 | 1.800 |
Why?
|
| Health Services Accessibility | 7 | 2026 | 145 | 1.800 |
Why?
|
| Glaucoma, Angle-Closure | 9 | 2023 | 10 | 1.800 |
Why?
|
| Risk Assessment | 9 | 2025 | 197 | 1.800 |
Why?
|
| Glaucoma, Neovascular | 3 | 2025 | 7 | 1.800 |
Why?
|
| Fractures, Bone | 8 | 2017 | 21 | 1.790 |
Why?
|
| Incidence | 21 | 2025 | 197 | 1.790 |
Why?
|
| Eyeglasses | 6 | 2016 | 8 | 1.750 |
Why?
|
| Accidental Falls | 7 | 2017 | 10 | 1.750 |
Why?
|
| Social Class | 2 | 2025 | 46 | 1.730 |
Why?
|
| Academies and Institutes | 5 | 2024 | 8 | 1.670 |
Why?
|
| Nutrition Surveys | 6 | 2020 | 67 | 1.670 |
Why?
|
| Registries | 4 | 2024 | 63 | 1.580 |
Why?
|
| Population Health | 3 | 2023 | 7 | 1.540 |
Why?
|
| Leadership | 2 | 2024 | 22 | 1.510 |
Why?
|
| Antihypertensive Agents | 16 | 2019 | 56 | 1.490 |
Why?
|
| Allergens | 3 | 2018 | 3 | 1.480 |
Why?
|
| Vision, Binocular | 4 | 2017 | 4 | 1.470 |
Why?
|
| Healthcare Disparities | 4 | 2025 | 83 | 1.390 |
Why?
|
| Nerve Fibers | 16 | 2025 | 17 | 1.360 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2015 | 49 | 1.350 |
Why?
|
| Program Evaluation | 2 | 2026 | 46 | 1.340 |
Why?
|
| Child, Preschool | 18 | 2026 | 258 | 1.300 |
Why?
|
| Disease Progression | 22 | 2025 | 170 | 1.280 |
Why?
|
| Population Surveillance | 5 | 2020 | 30 | 1.270 |
Why?
|
| Ocular Hypertension | 22 | 2017 | 24 | 1.260 |
Why?
|
| Surveys and Questionnaires | 15 | 2020 | 280 | 1.200 |
Why?
|
| Scotoma | 4 | 2012 | 4 | 1.160 |
Why?
|
| Child | 23 | 2025 | 524 | 1.160 |
Why?
|
| Treatment Outcome | 26 | 2025 | 500 | 1.140 |
Why?
|
| Tonometry, Ocular | 24 | 2020 | 26 | 1.140 |
Why?
|
| Odds Ratio | 13 | 2025 | 82 | 1.120 |
Why?
|
| Women's Health | 6 | 2018 | 24 | 1.120 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 84 | 1.120 |
Why?
|
| Societies, Medical | 4 | 2024 | 67 | 1.090 |
Why?
|
| Rural Population | 2 | 2026 | 16 | 1.090 |
Why?
|
| Public Health | 2 | 2026 | 40 | 1.060 |
Why?
|
| Vision, Ocular | 4 | 2022 | 7 | 1.060 |
Why?
|
| Retinal Vein Occlusion | 2 | 2025 | 2 | 1.010 |
Why?
|
| Blood Pressure | 8 | 2023 | 112 | 1.000 |
Why?
|
| Macula Lutea | 4 | 2020 | 6 | 0.970 |
Why?
|
| Mobile Health Units | 1 | 2026 | 2 | 0.970 |
Why?
|
| Musculoskeletal System | 2 | 2017 | 4 | 0.960 |
Why?
|
| Low Tension Glaucoma | 1 | 2025 | 1 | 0.950 |
Why?
|
| Oculomotor Muscles | 8 | 2020 | 9 | 0.930 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2025 | 1 | 0.920 |
Why?
|
| Ciliary Body | 4 | 2019 | 10 | 0.920 |
Why?
|
| Air Pollution, Indoor | 2 | 2015 | 3 | 0.920 |
Why?
|
| Immunoglobulin E | 2 | 2015 | 3 | 0.920 |
Why?
|
| Air Pollutants | 2 | 2015 | 6 | 0.920 |
Why?
|
| Dementia | 2 | 2024 | 14 | 0.900 |
Why?
|
| Young Adult | 16 | 2025 | 567 | 0.890 |
Why?
|
| Filtering Surgery | 4 | 2018 | 6 | 0.880 |
Why?
|
| Sickness Impact Profile | 5 | 2020 | 10 | 0.880 |
Why?
|
| Laser Therapy | 12 | 2015 | 16 | 0.870 |
Why?
|
| Faculty, Medical | 1 | 2024 | 17 | 0.860 |
Why?
|
| Optic Nerve | 9 | 2025 | 12 | 0.840 |
Why?
|
| Urban Population | 4 | 2019 | 85 | 0.830 |
Why?
|
| Macular Edema | 3 | 2025 | 9 | 0.830 |
Why?
|
| Insurance Claim Review | 3 | 2014 | 8 | 0.820 |
Why?
|
| Global Health | 1 | 2024 | 54 | 0.810 |
Why?
|
| Laser Coagulation | 2 | 2019 | 6 | 0.810 |
Why?
|
| Retinal Vessels | 4 | 2019 | 12 | 0.790 |
Why?
|
| Eye Movements | 5 | 2025 | 7 | 0.790 |
Why?
|
| Greece | 15 | 2019 | 15 | 0.790 |
Why?
|
| Public Health Surveillance | 1 | 2023 | 3 | 0.780 |
Why?
|
| Ophthalmologic Surgical Procedures | 5 | 2017 | 6 | 0.780 |
Why?
|
| Retinal Detachment | 2 | 2022 | 9 | 0.760 |
Why?
|
| Autism Spectrum Disorder | 2 | 2020 | 23 | 0.750 |
Why?
|
| Optometrists | 1 | 2022 | 2 | 0.750 |
Why?
|
| Ophthalmologists | 1 | 2022 | 3 | 0.750 |
Why?
|
| Cohort Studies | 15 | 2023 | 285 | 0.740 |
Why?
|
| Keratoplasty, Penetrating | 3 | 2017 | 6 | 0.730 |
Why?
|
| Forecasting | 4 | 2019 | 19 | 0.730 |
Why?
|
| Health Fairs | 1 | 2021 | 1 | 0.710 |
Why?
|
| Mobile Applications | 1 | 2021 | 4 | 0.710 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 73 | 0.700 |
Why?
|
| Dexamethasone | 2 | 2022 | 30 | 0.690 |
Why?
|
| Hypertension | 4 | 2019 | 147 | 0.690 |
Why?
|
| Lens, Crystalline | 2 | 2018 | 5 | 0.690 |
Why?
|
| Schools | 2 | 2018 | 25 | 0.670 |
Why?
|
| Refraction, Ocular | 2 | 2020 | 3 | 0.670 |
Why?
|
| Osteoporosis, Postmenopausal | 8 | 2012 | 9 | 0.650 |
Why?
|
| Laser-Doppler Flowmetry | 3 | 2019 | 5 | 0.650 |
Why?
|
| Health Services Research | 6 | 2014 | 27 | 0.640 |
Why?
|
| Hip Fractures | 2 | 2012 | 9 | 0.620 |
Why?
|
| Adolescent | 16 | 2025 | 869 | 0.620 |
Why?
|
| Personal Autonomy | 1 | 2019 | 6 | 0.620 |
Why?
|
| Ranibizumab | 2 | 2025 | 2 | 0.620 |
Why?
|
| Exercise | 1 | 2020 | 55 | 0.620 |
Why?
|
| Bevacizumab | 2 | 2025 | 4 | 0.620 |
Why?
|
| Los Angeles | 6 | 2026 | 321 | 0.620 |
Why?
|
| Anterior Chamber | 5 | 2015 | 11 | 0.600 |
Why?
|
| Corneal Transplantation | 2 | 2018 | 7 | 0.600 |
Why?
|
| Aqueous Humor | 4 | 2019 | 13 | 0.590 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2025 | 64 | 0.580 |
Why?
|
| Ocular Hypotension | 2 | 2017 | 3 | 0.580 |
Why?
|
| Eye Infections, Bacterial | 2 | 2015 | 15 | 0.580 |
Why?
|
| Visually Impaired Persons | 2 | 2017 | 2 | 0.580 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2018 | 1 | 0.560 |
Why?
|
| Logistic Models | 9 | 2018 | 165 | 0.560 |
Why?
|
| Case-Control Studies | 13 | 2025 | 108 | 0.560 |
Why?
|
| Alkylating Agents | 6 | 2025 | 7 | 0.560 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2018 | 25 | 0.560 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 58 | 0.560 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2019 | 82 | 0.550 |
Why?
|
| Occupational Exposure | 2 | 2025 | 12 | 0.550 |
Why?
|
| Mydriatics | 2 | 2021 | 4 | 0.550 |
Why?
|
| Dietary Fats | 1 | 2018 | 19 | 0.550 |
Why?
|
| Coffee | 1 | 2017 | 2 | 0.550 |
Why?
|
| Carbonated Beverages | 1 | 2017 | 3 | 0.550 |
Why?
|
| Reoperation | 7 | 2025 | 17 | 0.550 |
Why?
|
| Fatty Acids | 1 | 2018 | 25 | 0.550 |
Why?
|
| Parents | 3 | 2022 | 42 | 0.550 |
Why?
|
| Lenses, Intraocular | 2 | 2015 | 6 | 0.550 |
Why?
|
| Tea | 1 | 2017 | 6 | 0.540 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 72 | 0.540 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 20 | 0.540 |
Why?
|
| Mitomycin | 5 | 2025 | 5 | 0.530 |
Why?
|
| School Nursing | 2 | 2014 | 2 | 0.520 |
Why?
|
| Prostaglandins, Synthetic | 4 | 2020 | 4 | 0.520 |
Why?
|
| Pre-Eclampsia | 1 | 2017 | 12 | 0.520 |
Why?
|
| Health Status | 5 | 2013 | 83 | 0.510 |
Why?
|
| Glucocorticoids | 1 | 2017 | 65 | 0.500 |
Why?
|
| Neoplasms | 2 | 2018 | 92 | 0.500 |
Why?
|
| Health Education | 3 | 2015 | 55 | 0.500 |
Why?
|
| Prosthesis Implantation | 10 | 2020 | 15 | 0.500 |
Why?
|
| Prostheses and Implants | 4 | 1997 | 10 | 0.490 |
Why?
|
| National Eye Institute (U.S.) | 2 | 2013 | 2 | 0.490 |
Why?
|
| Quality Assurance, Health Care | 2 | 2011 | 17 | 0.480 |
Why?
|
| Health Resources | 2 | 2014 | 12 | 0.470 |
Why?
|
| Time Factors | 8 | 2016 | 321 | 0.470 |
Why?
|
| Health Care Costs | 5 | 2016 | 30 | 0.470 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 7 | 0.470 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2014 | 8 | 0.450 |
Why?
|
| Eye Proteins | 3 | 2025 | 10 | 0.450 |
Why?
|
| Radiation Monitoring | 2 | 2015 | 3 | 0.450 |
Why?
|
| Guideline Adherence | 3 | 2011 | 18 | 0.430 |
Why?
|
| Residence Characteristics | 2 | 2015 | 36 | 0.430 |
Why?
|
| School Teachers | 1 | 2014 | 2 | 0.430 |
Why?
|
| Cytoskeletal Proteins | 2 | 2025 | 6 | 0.410 |
Why?
|
| Glycoproteins | 2 | 2025 | 10 | 0.410 |
Why?
|
| Evidence-Based Medicine | 2 | 2004 | 28 | 0.400 |
Why?
|
| Longitudinal Studies | 11 | 2025 | 140 | 0.400 |
Why?
|
| Health Services Needs and Demand | 4 | 2016 | 32 | 0.400 |
Why?
|
| Gonioscopy | 5 | 2015 | 6 | 0.400 |
Why?
|
| Phacoemulsification | 3 | 2020 | 7 | 0.400 |
Why?
|
| School Health Services | 1 | 2013 | 9 | 0.390 |
Why?
|
| Timolol | 4 | 2003 | 5 | 0.390 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 26 | 0.390 |
Why?
|
| Ophthalmoscopy | 10 | 2014 | 15 | 0.390 |
Why?
|
| Blindness | 6 | 2018 | 11 | 0.390 |
Why?
|
| Diabetes Mellitus | 3 | 2012 | 208 | 0.380 |
Why?
|
| Fee-for-Service Plans | 4 | 2017 | 8 | 0.380 |
Why?
|
| Pupil | 1 | 2012 | 1 | 0.380 |
Why?
|
| Prognosis | 5 | 2019 | 220 | 0.380 |
Why?
|
| Iron, Dietary | 1 | 2012 | 1 | 0.380 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 2 | 0.380 |
Why?
|
| Diet | 3 | 2019 | 111 | 0.370 |
Why?
|
| Fruit | 2 | 2012 | 10 | 0.370 |
Why?
|
| Vegetables | 2 | 2012 | 8 | 0.370 |
Why?
|
| Retinal Neoplasms | 2 | 2023 | 2 | 0.370 |
Why?
|
| Retinoblastoma | 2 | 2023 | 3 | 0.370 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2025 | 6 | 0.370 |
Why?
|
| Dietary Supplements | 1 | 2012 | 44 | 0.360 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 169 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2025 | 30 | 0.360 |
Why?
|
| Statistics as Topic | 2 | 2009 | 16 | 0.360 |
Why?
|
| Mandatory Programs | 1 | 2011 | 1 | 0.360 |
Why?
|
| Databases, Factual | 6 | 2025 | 81 | 0.340 |
Why?
|
| Physician-Patient Relations | 3 | 2016 | 29 | 0.340 |
Why?
|
| Smoking | 2 | 2023 | 86 | 0.340 |
Why?
|
| Academic Medical Centers | 2 | 2024 | 23 | 0.340 |
Why?
|
| DNA | 2 | 2025 | 39 | 0.330 |
Why?
|
| Legislation, Hospital | 1 | 2010 | 1 | 0.330 |
Why?
|
| Lighting | 1 | 2010 | 1 | 0.330 |
Why?
|
| Phototherapy | 1 | 2010 | 2 | 0.330 |
Why?
|
| Comorbidity | 6 | 2018 | 147 | 0.330 |
Why?
|
| Radiation Injuries | 1 | 2010 | 9 | 0.330 |
Why?
|
| Intravitreal Injections | 3 | 2025 | 6 | 0.330 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 13 | 0.320 |
Why?
|
| Estrogen Replacement Therapy | 3 | 2008 | 12 | 0.320 |
Why?
|
| Age Distribution | 6 | 2018 | 45 | 0.320 |
Why?
|
| Infant | 11 | 2023 | 187 | 0.320 |
Why?
|
| Uveitis | 3 | 2021 | 53 | 0.310 |
Why?
|
| African Americans | 3 | 2018 | 264 | 0.310 |
Why?
|
| Sex Distribution | 5 | 2018 | 44 | 0.310 |
Why?
|
| Cause of Death | 3 | 2018 | 82 | 0.310 |
Why?
|
| Health Surveys | 5 | 2018 | 75 | 0.310 |
Why?
|
| Foreign-Body Migration | 3 | 2009 | 4 | 0.310 |
Why?
|
| Contrast Sensitivity | 3 | 2017 | 13 | 0.290 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 65 | 0.290 |
Why?
|
| Sensitivity and Specificity | 6 | 2021 | 98 | 0.280 |
Why?
|
| Retinoscopy | 3 | 2018 | 8 | 0.280 |
Why?
|
| Corneal Diseases | 3 | 2018 | 9 | 0.280 |
Why?
|
| Data Warehousing | 3 | 2023 | 3 | 0.270 |
Why?
|
| Reproducibility of Results | 9 | 2018 | 112 | 0.270 |
Why?
|
| Infant, Newborn | 7 | 2023 | 199 | 0.270 |
Why?
|
| Drug Utilization | 1 | 2007 | 8 | 0.270 |
Why?
|
| Linear Models | 7 | 2013 | 41 | 0.270 |
Why?
|
| Caregivers | 2 | 2019 | 29 | 0.270 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 197 | 0.270 |
Why?
|
| Photography | 9 | 2013 | 26 | 0.270 |
Why?
|
| Geography | 2 | 2020 | 5 | 0.270 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2016 | 11 | 0.250 |
Why?
|
| Pregnancy | 5 | 2023 | 599 | 0.250 |
Why?
|
| Anterior Eye Segment | 3 | 2015 | 9 | 0.250 |
Why?
|
| International Classification of Diseases | 1 | 2006 | 8 | 0.240 |
Why?
|
| Animals | 14 | 2020 | 1875 | 0.240 |
Why?
|
| Amino Acid Oxidoreductases | 2 | 2017 | 4 | 0.240 |
Why?
|
| Mutation | 2 | 2025 | 97 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 1 | 2026 | 48 | 0.240 |
Why?
|
| Cognition Disorders | 3 | 2015 | 19 | 0.240 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 10 | 0.230 |
Why?
|
| Pregnancy Complications | 1 | 2005 | 44 | 0.230 |
Why?
|
| Lipids | 2 | 2003 | 35 | 0.230 |
Why?
|
| Health Services | 2 | 2007 | 12 | 0.230 |
Why?
|
| Subarachnoid Space | 1 | 2025 | 1 | 0.220 |
Why?
|
| Choroid | 2 | 2020 | 4 | 0.220 |
Why?
|
| Patient Care | 1 | 2004 | 5 | 0.220 |
Why?
|
| Publications | 1 | 2004 | 5 | 0.220 |
Why?
|
| Blepharoplasty | 1 | 2004 | 1 | 0.210 |
Why?
|
| Endpoint Determination | 3 | 2015 | 3 | 0.210 |
Why?
|
| Frail Elderly | 1 | 2004 | 9 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 24 | 0.210 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 8 | 0.210 |
Why?
|
| Conjunctiva | 2 | 2016 | 9 | 0.210 |
Why?
|
| Ophthalmic Solutions | 7 | 2016 | 18 | 0.210 |
Why?
|
| Research Design | 2 | 2023 | 41 | 0.210 |
Why?
|
| Geriatrics | 1 | 2004 | 4 | 0.210 |
Why?
|
| Research | 1 | 2004 | 26 | 0.210 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2023 | 2 | 0.210 |
Why?
|
| Keratoconjunctivitis | 1 | 2023 | 2 | 0.210 |
Why?
|
| Thiophenes | 1 | 2003 | 3 | 0.210 |
Why?
|
| Sulfonamides | 1 | 2003 | 17 | 0.210 |
Why?
|
| Age Factors | 3 | 2019 | 193 | 0.210 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 8 | 0.210 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 21 | 0.200 |
Why?
|
| Neurofibromatosis 1 | 1 | 2023 | 1 | 0.200 |
Why?
|
| Optic Nerve Glioma | 1 | 2023 | 1 | 0.200 |
Why?
|
| Bayes Theorem | 4 | 2025 | 25 | 0.200 |
Why?
|
| Melanoma | 2 | 2021 | 14 | 0.200 |
Why?
|
| Depression | 3 | 2015 | 128 | 0.190 |
Why?
|
| Professional Practice | 1 | 2002 | 2 | 0.190 |
Why?
|
| Touch Perception | 1 | 2022 | 1 | 0.190 |
Why?
|
| Mother-Child Relations | 1 | 2022 | 3 | 0.190 |
Why?
|
| Economics, Medical | 1 | 2002 | 1 | 0.190 |
Why?
|
| Insurance, Physician Services | 1 | 2002 | 1 | 0.190 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2002 | 3 | 0.190 |
Why?
|
| Infant, Premature, Diseases | 1 | 2022 | 7 | 0.190 |
Why?
|
| Specialization | 1 | 2002 | 17 | 0.190 |
Why?
|
| Premature Birth | 1 | 2022 | 8 | 0.190 |
Why?
|
| Steroids | 1 | 2022 | 8 | 0.190 |
Why?
|
| Data Collection | 2 | 2014 | 38 | 0.190 |
Why?
|
| Algorithms | 5 | 2017 | 83 | 0.180 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2001 | 2 | 0.180 |
Why?
|
| Observer Variation | 4 | 2014 | 11 | 0.180 |
Why?
|
| Fractures, Spontaneous | 3 | 2010 | 4 | 0.180 |
Why?
|
| Pseudophakia | 1 | 2001 | 1 | 0.180 |
Why?
|
| Antimetabolites | 1 | 2001 | 6 | 0.180 |
Why?
|
| Aging | 2 | 2019 | 105 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2021 | 28 | 0.180 |
Why?
|
| Technology | 1 | 2021 | 2 | 0.180 |
Why?
|
| Microcephaly | 1 | 2021 | 2 | 0.180 |
Why?
|
| Zika Virus Infection | 1 | 2021 | 3 | 0.180 |
Why?
|
| Zika Virus | 1 | 2021 | 3 | 0.180 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2023 | 93 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 17 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 11 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2022 | 83 | 0.170 |
Why?
|
| Ultraviolet Rays | 2 | 2025 | 4 | 0.170 |
Why?
|
| Sensory Deprivation | 1 | 2021 | 2 | 0.170 |
Why?
|
| Uveal Neoplasms | 1 | 2021 | 3 | 0.170 |
Why?
|
| Atropine | 1 | 2021 | 17 | 0.170 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 9 | 0.170 |
Why?
|
| Tomography | 5 | 2013 | 6 | 0.170 |
Why?
|
| Axons | 2 | 2012 | 3 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 19 | 0.170 |
Why?
|
| Hospitals, Veterans | 2 | 2018 | 9 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2020 | 2 | 0.170 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 3 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2020 | 16 | 0.170 |
Why?
|
| Datasets as Topic | 1 | 2020 | 5 | 0.170 |
Why?
|
| Focus Groups | 3 | 2016 | 46 | 0.170 |
Why?
|
| Uveitis, Anterior | 1 | 2020 | 16 | 0.170 |
Why?
|
| Clonidine | 2 | 1990 | 3 | 0.160 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 50 | 0.160 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 8 | 0.160 |
Why?
|
| Graft Survival | 2 | 2018 | 36 | 0.160 |
Why?
|
| Prostaglandins | 2 | 2016 | 7 | 0.160 |
Why?
|
| Anisometropia | 1 | 2019 | 1 | 0.160 |
Why?
|
| Hyperopia | 1 | 2019 | 3 | 0.160 |
Why?
|
| Astigmatism | 1 | 2019 | 3 | 0.160 |
Why?
|
| Myopia | 1 | 2019 | 4 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2020 | 69 | 0.150 |
Why?
|
| Intellectual Disability | 1 | 2019 | 7 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2013 | 118 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2015 | 89 | 0.150 |
Why?
|
| Acute Disease | 2 | 2017 | 91 | 0.150 |
Why?
|
| Perception | 2 | 2022 | 19 | 0.150 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 16 | 0.150 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 2 | 2016 | 2 | 0.150 |
Why?
|
| Lasers, Solid-State | 1 | 2019 | 3 | 0.150 |
Why?
|
| Endoscopy | 1 | 2019 | 7 | 0.150 |
Why?
|
| Double-Blind Method | 6 | 2015 | 101 | 0.150 |
Why?
|
| Calcium Channels | 2 | 2017 | 8 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2018 | 2 | 0.140 |
Why?
|
| Motor Vehicles | 1 | 2018 | 1 | 0.140 |
Why?
|
| Iris | 2 | 2015 | 5 | 0.140 |
Why?
|
| Collagen | 2 | 2015 | 31 | 0.140 |
Why?
|
| Drainage | 2 | 2002 | 10 | 0.140 |
Why?
|
| Occupational Diseases | 2 | 2025 | 6 | 0.140 |
Why?
|
| Australia | 1 | 2018 | 16 | 0.140 |
Why?
|
| Orbit | 3 | 2025 | 6 | 0.140 |
Why?
|
| Fundus Oculi | 3 | 1996 | 20 | 0.140 |
Why?
|
| Ophthalmoplegia | 1 | 2017 | 1 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 104 | 0.140 |
Why?
|
| Beverages | 1 | 2017 | 8 | 0.140 |
Why?
|
| Polymorphism, Genetic | 2 | 2015 | 9 | 0.140 |
Why?
|
| Review Literature as Topic | 1 | 2017 | 1 | 0.130 |
Why?
|
| Models, Biological | 5 | 2014 | 64 | 0.130 |
Why?
|
| Administration, Topical | 4 | 2020 | 20 | 0.130 |
Why?
|
| Survival Rate | 1 | 2018 | 111 | 0.130 |
Why?
|
| Point Mutation | 1 | 2017 | 5 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2017 | 17 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 54 | 0.130 |
Why?
|
| Lens Diseases | 2 | 2014 | 2 | 0.130 |
Why?
|
| Iris Diseases | 2 | 2014 | 3 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 13 | 0.130 |
Why?
|
| State Medicine | 1 | 2016 | 1 | 0.130 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2016 | 2 | 0.130 |
Why?
|
| Health Care Sector | 1 | 2016 | 2 | 0.130 |
Why?
|
| Lasers | 7 | 2012 | 11 | 0.130 |
Why?
|
| Health Priorities | 1 | 2016 | 6 | 0.130 |
Why?
|
| Regional Blood Flow | 3 | 2019 | 17 | 0.130 |
Why?
|
| Retina | 1 | 1996 | 29 | 0.130 |
Why?
|
| Eyelids | 1 | 2016 | 2 | 0.130 |
Why?
|
| Retinal Diseases | 1 | 2017 | 48 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2016 | 38 | 0.120 |
Why?
|
| Orthoptics | 1 | 2016 | 1 | 0.120 |
Why?
|
| Community Networks | 1 | 2016 | 7 | 0.120 |
Why?
|
| Network Meta-Analysis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Family | 1 | 2016 | 27 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2025 | 33 | 0.120 |
Why?
|
| Physical Examination | 1 | 2016 | 7 | 0.120 |
Why?
|
| Facial Neoplasms | 1 | 2015 | 1 | 0.120 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2015 | 1 | 0.120 |
Why?
|
| Parasympathomimetics | 1 | 2015 | 1 | 0.120 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2015 | 2 | 0.120 |
Why?
|
| Aminoquinolines | 1 | 2015 | 7 | 0.120 |
Why?
|
| Gelatin | 1 | 2015 | 1 | 0.120 |
Why?
|
| Glycosaminoglycans | 1 | 2015 | 1 | 0.120 |
Why?
|
| Polytetrafluoroethylene | 1 | 2015 | 1 | 0.120 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 7 | 0.120 |
Why?
|
| Amnion | 1 | 2015 | 15 | 0.120 |
Why?
|
| Choroid Diseases | 1 | 1995 | 11 | 0.120 |
Why?
|
| Blood Pressure Determination | 2 | 2013 | 9 | 0.120 |
Why?
|
| Sensation Disorders | 1 | 2015 | 1 | 0.120 |
Why?
|
| Mitochondrial Diseases | 1 | 2015 | 1 | 0.120 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2015 | 4 | 0.120 |
Why?
|
| DNA, Mitochondrial | 1 | 2015 | 9 | 0.120 |
Why?
|
| Ultraviolet Therapy | 1 | 2015 | 1 | 0.120 |
Why?
|
| Osteoporotic Fractures | 1 | 2015 | 1 | 0.110 |
Why?
|
| United States Food and Drug Administration | 1 | 2015 | 7 | 0.110 |
Why?
|
| Acupuncture Therapy | 1 | 2015 | 4 | 0.110 |
Why?
|
| United Kingdom | 2 | 2016 | 7 | 0.110 |
Why?
|
| Genetic Variation | 2 | 2012 | 40 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 63 | 0.110 |
Why?
|
| Surgically-Created Structures | 1 | 2015 | 1 | 0.110 |
Why?
|
| Probability | 4 | 2013 | 20 | 0.110 |
Why?
|
| Eye Infections, Fungal | 1 | 2015 | 8 | 0.110 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 2015 | 2 | 0.110 |
Why?
|
| HLA-DRB1 Chains | 1 | 2015 | 3 | 0.110 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2015 | 3 | 0.110 |
Why?
|
| Population Groups | 1 | 2015 | 5 | 0.110 |
Why?
|
| Social Stigma | 1 | 2015 | 58 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 72 | 0.110 |
Why?
|
| Prosthesis Design | 1 | 2014 | 2 | 0.110 |
Why?
|
| Risk | 2 | 2012 | 43 | 0.110 |
Why?
|
| Hearing Loss | 2 | 2004 | 13 | 0.110 |
Why?
|
| Eye | 3 | 2024 | 14 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 153 | 0.110 |
Why?
|
| Achievement | 1 | 2014 | 2 | 0.110 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 3 | 0.110 |
Why?
|
| Bullying | 1 | 2014 | 9 | 0.110 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 1993 | 5 | 0.100 |
Why?
|
| Cholesterol, HDL | 2 | 1992 | 23 | 0.100 |
Why?
|
| Communication | 1 | 2014 | 31 | 0.100 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 127 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 8 | 0.100 |
Why?
|
| Glare | 1 | 2013 | 1 | 0.100 |
Why?
|
| Dark Adaptation | 1 | 2013 | 2 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 13 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2013 | 6 | 0.100 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 12 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 84 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 7 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2014 | 62 | 0.100 |
Why?
|
| Homeodomain Proteins | 2 | 2011 | 11 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2012 | 4 | 0.100 |
Why?
|
| Students | 1 | 2013 | 40 | 0.100 |
Why?
|
| Geographic Atrophy | 1 | 2012 | 1 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2012 | 23 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2012 | 12 | 0.090 |
Why?
|
| Alleles | 4 | 2017 | 22 | 0.090 |
Why?
|
| Capillaries | 2 | 2019 | 11 | 0.090 |
Why?
|
| Receptors, Chemokine | 1 | 2012 | 3 | 0.090 |
Why?
|
| Light Coagulation | 1 | 2012 | 2 | 0.090 |
Why?
|
| Levobunolol | 1 | 1992 | 1 | 0.090 |
Why?
|
| Antioxidants | 2 | 2012 | 37 | 0.090 |
Why?
|
| Frozen Sections | 1 | 2011 | 2 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2011 | 2 | 0.090 |
Why?
|
| Mohs Surgery | 1 | 2011 | 2 | 0.090 |
Why?
|
| Conflict of Interest | 1 | 2011 | 2 | 0.090 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2011 | 3 | 0.090 |
Why?
|
| Professional Misconduct | 1 | 2011 | 3 | 0.090 |
Why?
|
| Aniridia | 1 | 2011 | 1 | 0.090 |
Why?
|
| Eye Abnormalities | 1 | 2011 | 3 | 0.090 |
Why?
|
| Macaca fascicularis | 5 | 1996 | 8 | 0.090 |
Why?
|
| Persuasive Communication | 1 | 2011 | 1 | 0.090 |
Why?
|
| Public Health Practice | 1 | 2011 | 1 | 0.090 |
Why?
|
| Molteno Implants | 2 | 2017 | 2 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2011 | 53 | 0.080 |
Why?
|
| Prosthesis Failure | 3 | 2015 | 5 | 0.080 |
Why?
|
| False Positive Reactions | 4 | 2013 | 13 | 0.080 |
Why?
|
| Light | 1 | 2010 | 1 | 0.080 |
Why?
|
| Radiation Protection | 1 | 2010 | 4 | 0.080 |
Why?
|
| Mammary Tumor Virus, Mouse | 2 | 2001 | 2 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2001 | 3 | 0.080 |
Why?
|
| Cardiovascular System | 1 | 1990 | 21 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2020 | 34 | 0.080 |
Why?
|
| Graft Rejection | 1 | 2010 | 26 | 0.080 |
Why?
|
| Retinal Artery | 1 | 2010 | 2 | 0.080 |
Why?
|
| DNA Mutational Analysis | 2 | 2025 | 15 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2011 | 167 | 0.080 |
Why?
|
| Hydrophthalmos | 1 | 2009 | 1 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2009 | 10 | 0.080 |
Why?
|
| Hemodynamics | 1 | 1990 | 34 | 0.080 |
Why?
|
| Equipment Design | 3 | 2015 | 20 | 0.080 |
Why?
|
| Genotype | 4 | 2014 | 28 | 0.080 |
Why?
|
| Mortality | 1 | 2009 | 43 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 6 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 42 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2009 | 17 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2020 | 4 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 2 | 0.070 |
Why?
|
| Activities of Daily Living | 2 | 2007 | 19 | 0.070 |
Why?
|
| Estrogens | 1 | 2008 | 27 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2017 | 66 | 0.070 |
Why?
|
| Chromosome Aberrations | 2 | 1999 | 4 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 8 | 0.070 |
Why?
|
| Diet Records | 1 | 2008 | 6 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 10 | 0.070 |
Why?
|
| Automobile Driving | 2 | 2007 | 10 | 0.070 |
Why?
|
| Leukemia, Lymphoid | 1 | 1987 | 1 | 0.070 |
Why?
|
| Eosinophilia | 1 | 1987 | 3 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 43 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2007 | 9 | 0.070 |
Why?
|
| HIV Infections | 1 | 2012 | 432 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2007 | 44 | 0.070 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2011 | 11 | 0.070 |
Why?
|
| Choroidal Neovascularization | 1 | 2007 | 1 | 0.070 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 13 | 0.070 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2020 | 6 | 0.070 |
Why?
|
| ROC Curve | 2 | 2024 | 28 | 0.070 |
Why?
|
| Bone Density | 1 | 2007 | 25 | 0.070 |
Why?
|
| Distance Perception | 1 | 2007 | 1 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2004 | 49 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2007 | 2 | 0.060 |
Why?
|
| Fluorescein Angiography | 1 | 2007 | 10 | 0.060 |
Why?
|
| Heart Rate | 3 | 1992 | 29 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 38 | 0.060 |
Why?
|
| Prescriptions | 1 | 2006 | 3 | 0.060 |
Why?
|
| Mice | 6 | 2015 | 746 | 0.060 |
Why?
|
| Safety | 2 | 2003 | 18 | 0.060 |
Why?
|
| Equipment Failure | 2 | 2015 | 6 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2004 | 15 | 0.060 |
Why?
|
| Contraindications | 1 | 2005 | 3 | 0.060 |
Why?
|
| Silicone Elastomers | 1 | 2005 | 1 | 0.060 |
Why?
|
| Polypropylenes | 1 | 2005 | 2 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2025 | 4 | 0.060 |
Why?
|
| Nigeria | 1 | 2025 | 3 | 0.060 |
Why?
|
| Intraoperative Complications | 3 | 2010 | 8 | 0.060 |
Why?
|
| Managed Care Programs | 1 | 2005 | 8 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2025 | 11 | 0.060 |
Why?
|
| Radiation, Ionizing | 1 | 2025 | 3 | 0.060 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2025 | 1 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 1 | 2025 | 2 | 0.060 |
Why?
|
| Epithelium, Corneal | 1 | 2004 | 5 | 0.060 |
Why?
|
| Cysts | 1 | 2004 | 6 | 0.060 |
Why?
|
| Iran | 2 | 2015 | 68 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2024 | 22 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2024 | 35 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2004 | 10 | 0.050 |
Why?
|
| Biometry | 2 | 2014 | 3 | 0.050 |
Why?
|
| Nonoxynol | 1 | 2024 | 1 | 0.050 |
Why?
|
| Bimatoprost | 1 | 2003 | 1 | 0.050 |
Why?
|
| Cloprostenol | 1 | 2003 | 1 | 0.050 |
Why?
|
| Amides | 1 | 2003 | 4 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2003 | 20 | 0.050 |
Why?
|
| Recurrence | 2 | 2005 | 55 | 0.050 |
Why?
|
| Delivery Rooms | 1 | 2003 | 1 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 79 | 0.050 |
Why?
|
| Maternal Mortality | 1 | 2003 | 5 | 0.050 |
Why?
|
| Delivery, Obstetric | 1 | 2003 | 16 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2003 | 27 | 0.050 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 3 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 63 | 0.050 |
Why?
|
| Cotinine | 1 | 2023 | 21 | 0.050 |
Why?
|
| Eye Foreign Bodies | 1 | 2002 | 2 | 0.050 |
Why?
|
| False Negative Reactions | 2 | 2018 | 8 | 0.050 |
Why?
|
| Silicone Oils | 1 | 2002 | 4 | 0.050 |
Why?
|
| Plasmacytoma | 2 | 1999 | 2 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2022 | 23 | 0.050 |
Why?
|
| Parenting | 1 | 2022 | 18 | 0.050 |
Why?
|
| Genes, myc | 2 | 1999 | 2 | 0.050 |
Why?
|
| Trabecular Meshwork | 1 | 2021 | 1 | 0.050 |
Why?
|
| Protein Stability | 1 | 2021 | 3 | 0.050 |
Why?
|
| Age of Onset | 1 | 2021 | 16 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2015 | 72 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2021 | 10 | 0.040 |
Why?
|
| Africa | 1 | 2001 | 12 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 214 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 11 | 0.040 |
Why?
|
| Genes, erbB-2 | 1 | 2001 | 1 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2001 | 4 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 25 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2001 | 19 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2021 | 23 | 0.040 |
Why?
|
| Denmark | 1 | 2021 | 1 | 0.040 |
Why?
|
| Occupations | 1 | 2021 | 3 | 0.040 |
Why?
|
| Fathers | 1 | 2021 | 3 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2001 | 29 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2020 | 8 | 0.040 |
Why?
|
| Karyotyping | 2 | 1999 | 5 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 1990 | 42 | 0.040 |
Why?
|
| Stents | 1 | 2020 | 13 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 31 | 0.040 |
Why?
|
| Pigment Epithelium of Eye | 2 | 2008 | 5 | 0.040 |
Why?
|
| Sturge-Weber Syndrome | 1 | 1999 | 1 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2019 | 11 | 0.040 |
Why?
|
| Genes, Immunoglobulin | 1 | 1999 | 1 | 0.040 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1999 | 1 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 1999 | 2 | 0.040 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1999 | 2 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 70 | 0.040 |
Why?
|
| Base Sequence | 3 | 2011 | 65 | 0.040 |
Why?
|
| Retroviridae Infections | 1 | 1999 | 2 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1999 | 10 | 0.040 |
Why?
|
| Ophthalmoscopes | 1 | 1999 | 1 | 0.040 |
Why?
|
| Venules | 1 | 2019 | 2 | 0.040 |
Why?
|
| Arterioles | 1 | 2019 | 8 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2014 | 51 | 0.040 |
Why?
|
| Medical Records | 2 | 2011 | 23 | 0.040 |
Why?
|
| Haplotypes | 1 | 2017 | 3 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 6 | 0.030 |
Why?
|
| Molecular Chaperones | 1 | 2017 | 7 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2017 | 19 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 3 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 22 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 44 | 0.030 |
Why?
|
| Fovea Centralis | 1 | 2017 | 1 | 0.030 |
Why?
|
| Health Care Reform | 1 | 2016 | 5 | 0.030 |
Why?
|
| Friends | 1 | 2016 | 5 | 0.030 |
Why?
|
| Chromosomes | 1 | 1996 | 4 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 9 | 0.030 |
Why?
|
| Community Participation | 1 | 2016 | 13 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2017 | 190 | 0.030 |
Why?
|
| Dermis | 1 | 2016 | 4 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 20 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2016 | 8 | 0.030 |
Why?
|
| Travel | 1 | 2016 | 6 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1996 | 1 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1996 | 1 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 8 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 1996 | 13 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 1996 | 22 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2016 | 26 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 23 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2015 | 2 | 0.030 |
Why?
|
| India | 1 | 2015 | 13 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 1 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Clinical Governance | 1 | 2015 | 1 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2015 | 8 | 0.030 |
Why?
|
| Skin | 1 | 2015 | 10 | 0.030 |
Why?
|
| Radiation Exposure | 1 | 2015 | 6 | 0.030 |
Why?
|
| Patient Safety | 1 | 2015 | 10 | 0.030 |
Why?
|
| Device Approval | 1 | 2015 | 1 | 0.030 |
Why?
|
| Medical Device Legislation | 1 | 2015 | 1 | 0.030 |
Why?
|
| Nursing Homes | 1 | 1995 | 8 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 27 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 10 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 15 | 0.030 |
Why?
|
| Japan | 1 | 2015 | 6 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 16 | 0.030 |
Why?
|
| HLA-DP beta-Chains | 1 | 2015 | 1 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 8 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 15 | 0.030 |
Why?
|
| Mice, Transgenic | 3 | 2001 | 59 | 0.030 |
Why?
|
| Sensory Thresholds | 2 | 2005 | 2 | 0.030 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2014 | 47 | 0.030 |
Why?
|
| Disease Models, Animal | 3 | 2001 | 231 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 258 | 0.030 |
Why?
|
| Quinoxalines | 1 | 1993 | 11 | 0.030 |
Why?
|
| Cost Savings | 1 | 2013 | 13 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2012 | 3 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 11 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2012 | 6 | 0.020 |
Why?
|
| Viremia | 1 | 2012 | 8 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 21 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 29 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 39 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2012 | 1 | 0.020 |
Why?
|
| Genotyping Techniques | 1 | 2012 | 2 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2012 | 2 | 0.020 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2012 | 2 | 0.020 |
Why?
|
| HIV-1 | 1 | 2012 | 36 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 1992 | 11 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 65 | 0.020 |
Why?
|
| Eye Color | 1 | 1991 | 1 | 0.020 |
Why?
|
| Melanins | 1 | 1991 | 1 | 0.020 |
Why?
|
| Uvea | 1 | 1991 | 1 | 0.020 |
Why?
|
| Sclera | 1 | 1991 | 7 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 8 | 0.020 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 7 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 9 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2011 | 6 | 0.020 |
Why?
|
| Hotlines | 1 | 2011 | 1 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2011 | 11 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 25 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 91 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2011 | 61 | 0.020 |
Why?
|
| Exercise Test | 1 | 1990 | 9 | 0.020 |
Why?
|
| Corneal Edema | 1 | 2010 | 3 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 4 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2001 | 5 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1990 | 63 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 155 | 0.020 |
Why?
|
| Ophthalmodynamometry | 1 | 2010 | 1 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1990 | 48 | 0.020 |
Why?
|
| Body Weight | 1 | 1990 | 90 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 40 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1990 | 4 | 0.020 |
Why?
|
| Asian Americans | 1 | 2009 | 4 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2009 | 4 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 1999 | 46 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 1999 | 38 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 2008 | 4 | 0.020 |
Why?
|
| Diplopia | 1 | 2008 | 4 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 12 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2001 | 170 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 1987 | 1 | 0.020 |
Why?
|
| Fibrosis | 1 | 2008 | 53 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 15 | 0.020 |
Why?
|
| Cognition | 1 | 2007 | 30 | 0.020 |
Why?
|
| Death Certificates | 1 | 2006 | 3 | 0.020 |
Why?
|
| Diastole | 1 | 2006 | 4 | 0.020 |
Why?
|
| Systole | 1 | 2006 | 7 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2007 | 145 | 0.020 |
Why?
|
| Drug Costs | 1 | 2006 | 11 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2005 | 1 | 0.010 |
Why?
|
| Cryotherapy | 1 | 2004 | 7 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2004 | 15 | 0.010 |
Why?
|
| Decision Making | 1 | 2004 | 25 | 0.010 |
Why?
|
| Random Allocation | 1 | 2004 | 27 | 0.010 |
Why?
|
| Dominican Republic | 1 | 2003 | 4 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 36 | 0.010 |
Why?
|
| Aphakia | 1 | 2002 | 1 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2002 | 11 | 0.010 |
Why?
|
| Hospitalization | 1 | 2003 | 128 | 0.010 |
Why?
|
| Fluorophotometry | 1 | 2001 | 4 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2001 | 6 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2001 | 2 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2001 | 16 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2001 | 150 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1999 | 2 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 38 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 90 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 1999 | 1 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1999 | 1 | 0.010 |
Why?
|
| Ploidies | 1 | 1999 | 1 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1999 | 6 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 1999 | 4 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1999 | 3 | 0.010 |
Why?
|
| Life Tables | 1 | 1999 | 1 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1996 | 3 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 1996 | 7 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 21 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1996 | 18 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 1996 | 22 | 0.010 |
Why?
|
| Proteins | 1 | 1996 | 41 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1996 | 4 | 0.010 |
Why?
|
| Antigens | 1 | 1996 | 3 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1996 | 7 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1996 | 7 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1996 | 18 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 23 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1996 | 18 | 0.010 |
Why?
|
| Mice, Nude | 1 | 1996 | 41 | 0.010 |
Why?
|
| Gene Expression | 1 | 1996 | 77 | 0.010 |
Why?
|
| Baltimore | 1 | 1995 | 4 | 0.010 |
Why?
|
| Brimonidine Tartrate | 1 | 1993 | 1 | 0.010 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1993 | 1 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1993 | 25 | 0.010 |
Why?
|
| Cell Count | 1 | 1991 | 18 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 1990 | 1 | 0.010 |
Why?
|
| Optical Devices | 1 | 1990 | 1 | 0.010 |
Why?
|